ALS Program
Amyotrophic Lateral Sclerosis
PreclinicalActive
Key Facts
About Biorchestra
Biorchestra is a private, preclinical-stage biotech founded in 2013, headquartered in Daejeon, South Korea, with a U.S. presence. The company is pioneering RNA interference (RNAi) and messenger RNA (mRNA) therapeutics for challenging neurological conditions, leveraging its proprietary brain-targeted delivery technology. Its strategy involves advancing internal programs while seeking partnerships to expand its platform's application. As a pre-revenue entity, its success hinges on clinical validation of its delivery system and pipeline candidates.
View full company profileTherapeutic Areas
Other Amyotrophic Lateral Sclerosis Drugs
| Drug | Company | Phase |
|---|---|---|
| Cell Therapy for ALS | INCELL | Unknown |
| ALS Research | GliaPharm | Research |
| ALS Disease Model Service | NeuroProof | Pre-clinical |
| ALS Biomarker Program | Linus Biotechnology | Pre-clinical |
| ALS Research (post-RADICAVA) | Tanabe Pharma America | Preclinical/Research |
| Program(s) for ALS | AviadoBio | Pre-clinical |
| TCD601 for ALS | ITB Med | Phase 2 |
| ILB® for ALS | TikoMed | Phase 2 |
| ALS Patient-Led Research Initiative | BGI | Research |
| ALS Pathway Discovery | Anima Biotech | Preclinical |
| Pridopidine | Prilenia Therapeutics | Phase 3 |
| Foralumab (intranasal) | Tiziana Life Sciences | Phase 2 |